Blackhawk Growth’s SAC Pharma Announces Record August Revenue of CDN$460,000 and Includes Operational Update
Vancouver, British Columbia – TheNewswire – September 09, 2021 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (Frankfurt:0JJ) (OTC:BLRZF) (the “Company”), is excited to announce the record unaudited revenue in the month of August for Sac Pharma Partners USA (“SAC Pharma”), its wholly owned subsidiary, of CDN$460,000. Sac Pharma continues to show strong revenue growth. Revenue for the 8 months ended August 31, 2021 is a company record of CDN$1,842,000. Sac Pharma has also continued to show strong gross margins of greater than 80% and positive cash flow for the year to date. These results are due to increasing facility yields, and the strong demand for Sac Pharma’s premium products.
Sac Pharma is also very excited to announce that the next of its proprietary strains, “Morada” has completed the R&D testing approvals and has shown very high producing yield. The robust profile, color and potency has enabled Sac Pharma to be able to have pre-sold the entire production run of the new Morado premium product.
“Blackhawk is thrilled with the operating results and the continued development of very desirable proprietary strains”, states Frederick Pels, CEO of Blackhawk. “We are very happy to have such a strong brand in our portfolio of companies.”
Sac Pharma is operating at near capacity and expansion planning has begun.
Sac Pharma’s signature products include the coveted Black Truffle, White Truffle strains, along with Bacio and Gelato.
The Company cautions that figures for revenue and margin generated by Sac Pharma have not been audited and are based on calculations prepared by management. Actual results may differ from those reported in this release once these figures have been audited.
For more information on Blackhawk, please visit our website at:
https://www.blackhawkgrowth.com/
About Blackhawk Growth
Blackhawk is an investment holding looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods and MindBio Therapeutics. Blackhawk continues to bring its investments to cash flow and is growing at an exceeding pace.
The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A
Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.
Frederick Pels, Chief Executive Officer
(403)-991-7737
fred@blackhawkgrowth.com
Cautionary Note Regarding Forward-Looking Statement
All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the future prospects of the business of the Company and Sac Pharma USA. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.